ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
MWN-AI** Summary
ChemDiv has announced the extension of its Chemistry, Manufacturing, and Controls (CMC) services collaboration with Traws Pharma, Inc. (NASDAQ: TRAW) to advance ratutrelvir, an investigational oral antiviral treatment for COVID-19 currently in Phase 2 clinical trials. This announcement follows the recent dosing of the first patient in these trials, with top-line data expected by the end of 2025.
Ratutrelvir is a ritonavir-free Main protease (Mpro/3CL) inhibitor, designed to be effective against a range of SARS-CoV-2 variants, including those resistant to existing therapies. Its development involved ChemDiv's specialized medicinal chemistry and virology teams, capitalizing on advanced tools from Molsoft for rational drug design and Expert Systems for predictive pharmacology. This unique formulation is poised to differentiate itself from current treatments by offering a streamlined 10-day treatment regimen without the need for ritonavir, mitigating potential drug-drug interactions.
Traws Pharma, in collaboration with Expert Systems, is extending its efforts to bolster the clinical development of ratutrelvir, utilizing cutting-edge AI technology to enhance safety pharmacology predictions and streamline regulatory processes. The current Phase 2 trials include a non-inferiority study comparing ratutrelvir to PAXLOVID® and a trial targeting patients who are ineligible for PAXLOVID®.
With early studies indicating promising pharmacokinetics, including maintained plasma levels significantly above the effective concentration, ratutrelvir has the potential to reduce both viral rebounds and the risk of Long COVID complications. As ChemDiv continues to provide integrated drug development support, they are committed to ensuring the successful progression of ratutrelvir through clinical stages and regulatory submissions.
MWN-AI** Analysis
The recent announcement from ChemDiv regarding the extension of its CMC services collaboration for ratutrelvir is a significant development in the biotechnology sector, particularly in the context of COVID-19 therapeutics. With Traws Pharma advancing ratutrelvir to Phase 2 clinical trials, this oral antiviral treatment is positioned to potentially outperform existing therapies like PAXLOVID®.
Investors should closely monitor Traws Pharma (NASDAQ: TRAW), as positive results from the ongoing Phase 2 studies could substantially impact its stock price. The fact that ratutrelvir has been designed to avoid ritonavir co-administration—a common factor that complicates treatment regimens—could make it particularly attractive to healthcare providers and patients alike. The simplified 10-day dosing regimen and high potency against a broad spectrum of SARS-CoV-2 variants are notable advantages that differentiate ratutrelvir in a crowded market.
Moreover, ChemDiv's strategic partnership with Expert Systems to employ AI-enabled predictive pharmacology tools enhances the likelihood of successful clinical trial outcomes. This combination of innovative drug discovery techniques and advanced safety profiling could de-risk the clinical development process, ultimately boosting investor confidence.
Given the increasing incidence of COVID-19 and the emergence of resistant strains, the demand for new and effective antiviral therapies remains high. Evaluating ratutrelvir’s potential in both newly diagnosed patients and those ineligible for existing treatments presents a compelling business case for Traws Pharma.
For investors, keeping an eye on the upcoming top-line data expected by the end of 2025 is crucial. If Traws Pharma can demonstrate ratutrelvir’s efficacy and safety, it may solidify its position in the market as a leading COVID-19 therapeutic, resulting in substantial gains for its shareholders. Thus, a bullish outlook on TRAW is warranted based on the promising developments from ChemDiv and the advancing clinical trial phase.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
SAN DIEGO, Oct. 30, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced the extension of its Chemistry, Manufacturing and Controls (CMC) services collaboration supporting the clinical development of ratutrelvir, a promising oral antiviral treatment for COVID-19. The announcement follows recent progress by Traws Pharma, Inc. (NASDAQ: TRAW), which dosed the first patient in Phase 2 studies of ratutrelvir in October 2025, with top-line data expected by year-end 2025.
Ratutrelvir, a ritonavir-free Main protease (Mpro/3CL) inhibitor, was discovered and developed ab initio from target to clinic by ChemDiv's medicinal chemistry and virology services teams. Leveraging Molsoft's rational drug design platform and Expert Systems' predictive pharmacology tools, ChemDiv developed ratutrelvir to differentiate from existing COVID-19 treatments by offering high potency against a broad range of native and resistant SARS-CoV-2 strains, a simplified 10-day treatment regimen, and elimination of ritonavir co-administration—potentially avoiding drug-drug interactions that limit patient eligibility for current therapies.
Expert Systems, which collaborated with ChemDiv during ratutrelvir's discovery phase, is now extending its contract with Traws Pharma to support further clinical development through a comprehensive predictive safety pharmacology program. This partnership leverages Expert Systems' advanced AI-enabled drug discovery platform to de-risk clinical progression and accelerate regulatory readiness.
ChemDiv's ongoing collaboration includes:
- CMC process research and scale-up for API (Active Pharmaceutical Ingredient) and DP (Drug Product) manufacturing supporting non-GLP and GLP studies,
- Medicinal chemistry support for backup series development,
- Translational pharmacology services utilizing computational modeling and wet-lab validation,
- Clinical pharmacology consulting to optimize dosing strategies for Phase 2 and beyond.
"We're proud to support the advancement of ratutrelvir from discovery through clinical development," said Ilya Baimetov, COO at ChemDiv. "By combining our integrated medicinal chemistry capabilities with Molsoft's rational design tools and Expert Systems' AI-driven predictive pharmacology, we created a differentiated COVID therapeutic with best-in-class potential. Our continued CMC support ensures Traws has the manufacturing infrastructure and analytical capabilities needed for successful clinical execution and regulatory submission."
Ratutrelvir is currently being evaluated in two Phase 2 studies: a non-inferiority trial comparing ratutrelvir to PAXLOVID® in newly diagnosed COVID-19 patients, and a single-arm trial in PAXLOVID®-ineligible patients—a vulnerable population with limited treatment options. Phase 1 studies demonstrated that ratutrelvir maintained plasma levels approximately 13 times above the EC?? with a 10-day, once-daily dosing regimen without ritonavir, potentially reducing the likelihood of viral rebound and Long COVID risk.
About Ratutrelvir
Ratutrelvir is an investigational oral, small molecule Mpro (3CL protease) inhibitor designed as a broadly acting treatment for SARS-CoV-2/COVID-19 without requiring ritonavir co-administration. Preclinical and Phase 1 studies showed ratutrelvir's differentiated activity against nirmatrelvir-resistant strains and favorable pharmacokinetic profile. Ratutrelvir is currently in Phase 2 clinical development by Traws Pharma.
About Expert Systems, Inc.
Expert Systems is an advanced accelerator platform equipped with a comprehensive, hybrid AI-based system covering the entire spectrum of preclinical drug discovery and early development phases, including target identification, virtual screening, non-clinical and clinical pharmacology, chemical liability assessment, and toxicology. Expert Systems supported ratutrelvir's development as part of its AI-assisted drug discovery accelerator program.
About Traws Pharma, Inc.
Traws Pharma (NASDAQ: TRAW) is a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases. The company is advancing investigational oral small molecule antiviral agents with potent activity against difficult-to-treat or resistant virus strains, including ratutrelvir for COVID-19 and tivoxavir marboxil for influenza.
About ChemDiv
ChemDiv is a fully integrated discovery partner from target to clinic, offering a library of over 12 million screening compounds, 2 trillion feasible chemistries for rational drug design, thousands of pre-designed chemical tool libraries, 70,000 building blocks, and a catalog of 45,000 inhibitors and drugs. Its services include custom medicinal chemistry, CMC, AI-powered CADD, computational pharmacology, lead optimization, translational biology, and clinical pharmacology support.
Media Contact:
ChemDiv, Inc.
+1 858 794 4860
chemdiv@chemdiv.com
www.chemdiv.com
SOURCE ChemDiv
FAQ**
How might the performance of ratutrelvir in the Phase 2 trials impact Traws Pharma Inc. TRAW's stock prices and market perception, especially considering its comparison to existing treatments like PAXLOVID®?
What specific metrics from the Phase 2 trials of ratutrelvir will investors be looking for to gauge the potential success of Traws Pharma Inc. TRAW in the competitive COVID-19 treatment landscape?
How does ChemDiv's extension of CMC services for ratutrelvir align with Traws Pharma Inc. TRAW's strategic goals in advancing innovative therapies for viral infections?
What are the potential risks for Traws Pharma Inc. TRAW if ratutrelvir's Phase 2 trials do not meet expectations, and how could this affect investor confidence in the company's future projects?
**MWN-AI FAQ is based on asking OpenAI questions about Traws Pharma Inc. (NASDAQ: TRAW).
NASDAQ: TRAW
TRAW Trading
0.52% G/L:
$1.92 Last:
25,199 Volume:
$1.73 Open:
